著者

林 誠 杉村 勇人 菅 幸生 河原 昌美 相宮 光二 宮本 謙一

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.35, no.2, pp.89-95, 2009 (Released:2010-02-07)

参考文献数

22

被引用文献数

10 13

---

Hiccups often occur in patients receiving cisplatin (CDDP)-based chemotherapy.In the present study,we investigated the incidence of hiccups in 162 patients who received CDDP as well as risk factors for developing hiccups.Hiccups occurred in 40 (25%) of the 162 patients,and 93% were men.Twenty-six of the patients had hiccups within 48 hr of CDDP,and in 31 of them the hiccups continued for between 1 and 4 days.Twenty-eight of the patients received medication (shitei-decoction,chlorpromazine,metoclopramide,etc.) to relieve hiccups,which was effective in 30% of them.Hiccups developed in patients with osteochondro sarcoma (56%),lung cancer (49%),pancreatic cancer (40%) and esophagus cancer (23%) receiving the following 4 chemotherapy regimens : CDDP+ADM+CAF (56%),CDDP+DTX (50%),CDDP+5 FU (40%),and CDDP+TS 1 (20%) respectively.The CDDP dosage (mg/m2)was higher in patients who had hiccups than in those who had none (80±22 vs 45±33,p< 0.0001)and there was a positive correlation was between CDDP dosage and incidence of hiccups (p<0.001),though all patients developing them received corticosteroids and 5 HT3 antagonists.Multiple logistic regression analysis showed that there were significant differences for the male sex (odds ratio (OR)=8,95% CI=1.5-45.6),CDDP dose (1.03,1.01-1.06),dexamethasone(≥16 mg) (19.4,3.9-95.2)and granisetron (6 mg) (20.9,3-143).We therefore concluded that the independent risk factors influencing the development of hiccups were the male sex and a high dose of CDDP in combination with dexamethasone(≥16 mg),and granisetron (6 mg).

著者

相宮 光二 宮川 慶子 林 誠 長岡 宏一 阿部 康治 北 俊之

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.36, no.7, pp.469-475, 2010 (Released:2012-03-10)

参考文献数

12

---

Sulbactam sodium-ampicillin sodium (hereinafter referred to as SBT/ABPC) injections are widely used for the treatment of infection and in view of this,we conducted a study to examine the therapeutic equivalence of original and generic preparations of SBT/ABPC.In it,we compared efficacy and safety in patients diagnosed with pneumonia,acute bronchitis,or acute bronchiolitis who received the original or a generic SBT/ABPC injection at the National Organization Kanazawa Medical Center from May 2007 to March 2008.We analyzed the efficacy endpoints of body temperature,white blood cell count,and CRP level and the safety endpoints of AST (GOT),ALT (GPT),and BUN in 121 subjects receiving the original preparation and 112 receiving the generic one.Our results suggest therapeutic equivalence for both efficacy and safety,and we conclude that the generic version can definitely be used as an alternative to the original preparation.